If you liked this article you might like

2016 Was a Terrible Year for Biotech but the Tweets Were on Point
Pfizer Finds Breaking Up Is Hard to Do
Sanofi Gains Boost from MS Treatments as Diabetes Drug Lantus Flounders
After FDA Approval, Merck Posts Better-Than-Expected Earnings